CYP4F2基因多态性影响华法林初始治疗效果的临床研究  

A clinical survey of the association between CYP4F2 gene polymorphism and oral warfarin dose in the initiated period

作　　者：陈涌斌 钟诗龙[1] 刘媛[2] 黄焕雷[3] 卢聪[3] 

机构地区：[1]广东省人民医院(广东省医学科学院)医学实验中心,广州510100 [2]广东省心血管病研究所心内科广东省人民医院(广东省医学科学院),广州510100 [3]广东省心血管病研究所心外科广东省人民医院(广东省医学科学院),广州510100

出　　处：《岭南心血管病杂志》2017年第2期182-185,193,共5页South China Journal of Cardiovascular Diseases

摘　　要：目的研究心脏瓣膜置换术后口服华法林抗凝治疗的初始剂量的个体化区别,分析CYP4F2 rs2108622基因型对口服华法林初始剂量的影响。方法入选广东省心血管病研究所2000年至2008年瓣膜置换术后口服华法林抗凝治疗的患者,回顾患者一般资料、临床资料、用药剂量、国际标准化比值(international normalizedratio,INR)和进入治疗窗时间(INR≥1.8)、超出治疗窗时间(INR>3.5)。结果本次研究共有769例患者资料齐全,民族均为中国汉族,其中CYP4F2基因型为CC型的患者占65.8%(n=506),CT型28.7%(n=221),TT型5.5%(n=42)。按基因型不同分别分析进入治疗窗(INR>1.8)和过度抗凝(INR>3.5)的时间发现,不同基因型之间比较,差异有统计学意义(P<0.05)。结论 CYP4F2基因型多态性对于口服华法林初始剂量存在一定的影响。Objectives To investigate the effect of genetic polymorphisms of CYP4F2 rs2108622 on the initial responses to warfarin in Chinese patients with heart valve replacement. Method A retrospective study was conducted in Chinese patients receiving oral warfarin for anticoagulation treatment after heart valve replacement in Guangdong Cardiovascular Institute from 2000 to 2008. General data, clinical data, warfarin dose, international normalized ratio （INR） and duration to the first INR within the therapeutic range （INR≥1.8） and duration to the first INR greater than 3.5 （INR〉3.5） were followed up. Results Totally 769 patients were recruited, and all of them were Han nationality. Among all the enrolled cases, CYP4F2 rs2108622 CC, CT and CC genotype frequencies were 65.8% （n=506）, 28.7% （n=221） and 5.5% （n=42）. There were significant differences between duration to the first INR≥1.8 and duration to the first INR〉3.5 among different genotypes （P〈0.05）. Conclusions There was significant difference in the warfarin initial dose among genotypes in CYP4F2 rs2108622.

关 键 词：华法林 CYP4F2 个体化用药 药代动力学 

分 类 号：R973.2[医药卫生—药品]